Switch theme
Sign up to access all valuation multiples
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
2005
160
LTM Revenue $10.5M
LTM EBITDA -$78.5M
$213M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Capricor Therapeutics has a last 12-month revenue (LTM) of $10.5M and a last 12-month EBITDA of -$78.5M.
In the most recent fiscal year, Capricor Therapeutics achieved revenue of $22.3M and an EBITDA of -$41.1M.
Capricor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Capricor Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.5M | XXX | $22.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$78.5M | XXX | -$41.1M | XXX | XXX | XXX |
| EBITDA Margin | -748% | XXX | -185% | XXX | XXX | XXX |
| EBIT | -$71.4M | XXX | -$42.6M | XXX | XXX | XXX |
| EBIT Margin | -680% | XXX | -191% | XXX | XXX | XXX |
| Net Profit | -$69.9M | XXX | -$40.5M | XXX | XXX | XXX |
| Net Margin | -665% | XXX | -182% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 12, 2025, Capricor Therapeutics's stock price is $8.
Capricor Therapeutics has current market cap of $357M, and EV of $213M.
See Capricor Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $213M | $357M | XXX | XXX | XXX | XXX | $-1.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 12, 2025, Capricor Therapeutics has market cap of $357M and EV of $213M.
Capricor Therapeutics's trades at 9.6x EV/Revenue multiple, and -5.2x EV/EBITDA.
Equity research analysts estimate Capricor Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Capricor Therapeutics has a P/E ratio of -5.1x.
See valuation multiples for Capricor Therapeutics and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $357M | XXX | $357M | XXX | XXX | XXX |
| EV (current) | $213M | XXX | $213M | XXX | XXX | XXX |
| EV/Revenue | 20.3x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBITDA | -2.7x | XXX | -5.2x | XXX | XXX | XXX |
| EV/EBIT | -3.0x | XXX | -5.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.1x | XXX | -8.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCapricor Therapeutics's last 12 month revenue growth is 605%
Capricor Therapeutics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Capricor Therapeutics's rule of 40 is 514% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Capricor Therapeutics's rule of X is 765% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Capricor Therapeutics and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 605% | XXX | 131% | XXX | XXX | XXX |
| EBITDA Margin | -748% | XXX | -185% | XXX | XXX | XXX |
| EBITDA Growth | -49% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 514% | XXX | 420% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 765% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 224% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 291% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Capricor Therapeutics acquired XXX companies to date.
Last acquisition by Capricor Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Capricor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Capricor Therapeutics founded? | Capricor Therapeutics was founded in 2005. |
| Where is Capricor Therapeutics headquartered? | Capricor Therapeutics is headquartered in United States of America. |
| How many employees does Capricor Therapeutics have? | As of today, Capricor Therapeutics has 160 employees. |
| Who is the CEO of Capricor Therapeutics? | Capricor Therapeutics's CEO is Dr. Linda Marban, PhD. |
| Is Capricor Therapeutics publicy listed? | Yes, Capricor Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Capricor Therapeutics? | Capricor Therapeutics trades under CAPR ticker. |
| When did Capricor Therapeutics go public? | Capricor Therapeutics went public in 2002. |
| Who are competitors of Capricor Therapeutics? | Similar companies to Capricor Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Capricor Therapeutics? | Capricor Therapeutics's current market cap is $357M |
| What is the current revenue of Capricor Therapeutics? | Capricor Therapeutics's last 12 months revenue is $10.5M. |
| What is the current revenue growth of Capricor Therapeutics? | Capricor Therapeutics revenue growth (NTM/LTM) is 605%. |
| What is the current EV/Revenue multiple of Capricor Therapeutics? | Current revenue multiple of Capricor Therapeutics is 20.3x. |
| Is Capricor Therapeutics profitable? | Yes, Capricor Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Capricor Therapeutics? | Capricor Therapeutics's last 12 months EBITDA is -$78.5M. |
| What is Capricor Therapeutics's EBITDA margin? | Capricor Therapeutics's last 12 months EBITDA margin is -748%. |
| What is the current EV/EBITDA multiple of Capricor Therapeutics? | Current EBITDA multiple of Capricor Therapeutics is -2.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
